First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Béla Ózsvári; Federica Sotgia; Michael P. Lisanti

doi:doi:10.18632/aging.103336

← Back

Research Paper Volume 12, Issue 11 pp 10162—10179

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Figure 11. A large mito-ribosome 9-gene signature predicts distant metastasis and tumor recurrence in ER(+) breast cancer patients. A 9-gene mito-ribosome signature effectively predicts distant metastasis in N=1,395 patients (HR=1.59; P=5e-05) and tumor recurrence in N=3,082 patients (HR=1.71; P<1e-16). See Supplementary Tables 4 and 5 and 5 DMFS, distant metastasis free survival; RFS, relapse free survival.